---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-036944"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:36:41.931848+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocuphire Q2 net loss $7.8M ($0.30/sh); cash $41.4M; VEGA-3 recruiting for presbyopia

## Summary
- Net loss $7.8M ($0.30/sh) vs $5.0M ($0.24) in Q2 2023; revenue from collaborator license $1.1M vs $3.7M.
- Cash $41.4M provides runway into mid-2025; R&D spend $6.1M (+30% YoY) driven by APX3330 manufacturing.
- VEGA-3 Phase 3 trial of phentolamine ophthalmic solution 0.75% for presbyopia now recruiting; topline 2025.
- LYNX-2 Phase 3 study for dim light disturbances enrollment strong; LYNX-3 study planned for 2024.
- Discussions with FDA ongoing for APX3330 Special Protocol Assessment in diabetic retinopathy.

## SEC filing metadata
- accession: 0001140361-24-036944
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036124036944/0001140361-24-036944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036124036944/ef20033986_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-036944
- JSON: https://secwatch.observer/filing/0001140361-24-036944.json
- Plain text: https://secwatch.observer/filing/0001140361-24-036944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.